

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden				
nours per respons	se 0.5			

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
Name and Address of Reporting Person* Kowalski John M	2. Date of Event Requiring Statement (Month/Day/Year) -03/12/2020		3. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]						
(Last) (First) (Middle) C/O BIOSIG TECHNOLOGIES, INC., 54 WILTON ROAD, 2ND FLOO				4. Relationship of Issuer (Check	Reporting Person all applicable)	Filed(Mon	5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) WESTPORT, CT 06880				X Officer (give title Other (specify below) VP of Sales		Applicable I _X_ Form fi	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person		
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)		rned		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock		107,000			D				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)		Security (Instr. 4)	Amount of Inderlying Derivative or Exercise Price of Derivative Security		se Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title Amour	nt or Number of		(I) (Instr. 5)			

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kowalski John M C/O BIOSIG TECHNOLOGIES, INC. 54 WILTON ROAD, 2ND FLOOR WESTPORT, CT 06880			VP of Sales			

Signatures

/s/ Kenneth L. Londoner, attorney-in-fact	03/12/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit Index Exhibit 24.1 Power of Attorney (furnished herewith)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

March 12, 2020

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kenneth L. Londoner as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for, in the name of, and on behalf of the undersigned, place and stead, in any and all capacities, (i) to execute any and all filings required to be made by the undersigned in the undersigned's capacity as an officer or director or both of BioSig Technologies, Inc. pursuant to Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), for, in the name of, and on behalf of the undersigned, (ii) to do and perform any and all acts for, in the name of, and on behalf of the undersigned which said attorney-in-fact determines may be necessary or appropriate to complete and execute any and all such filings, amendments, supplements, and/or exhibits, and any and all other document(s) in connection therewith, (iii) to file such filings, amendments, supplements, exhibits, and/or documents with any governmental office or agency, whether U.S., foreign, state or local government (including, without limitation, the U.S. Securities and Exchange Commission and state securities administrators or commissions), or any stock exchange or stock quotation system (including, without limitation, The NASDAQ Capital Market), as may be required under applicable laws or rules and regulations of any stock exchange or stock quotation system, and (iv) to perform any and all other acts that, in the opinion of said attorney-in-fact and agent, may be of benefit to, in the best interest of, or legally required by or for the undersigned, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purpose

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports under Section 13 or Section 16 of the Exchange Act (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), unless earlier revoked by the undersigned in a signed writing delivered to Kenneth L. Londoner.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed and effective as of the date first written above.

/s/ John Kowalski John Kowalski